cefixime has been researched along with Community Acquired Infection in 11 studies
Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized, double-blind multicenter study compared clarithromycin and cefixime as treatment for patients with community-acquired lower respiratory tract infections (n = 213)." | 9.07 | Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. ( Chick, TW; Neu, HC, 1993) |
| "Cefixime is an oral third generation cephalosporin, frequently used in respiratory tract infections (RTI) in the pediatric population." | 5.15 | Clinical role of Cefixime in community-acquired infections. ( Aliu, A; Basha, N; Daka, A; Doda-Ejupi, T; Dreshaj, Sh; Geca, Nj; Kabashi, S; Mustafa, A; Shala, N; Tolaj, IQ, 2011) |
| "This randomized, double-blind multicenter study compared clarithromycin and cefixime as treatment for patients with community-acquired lower respiratory tract infections (n = 213)." | 5.07 | Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. ( Chick, TW; Neu, HC, 1993) |
| " Single doses of each agent were administered and serum concentrations were collected over the standard dosing period of 24 h for all study regimens." | 2.70 | Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens. ( Ambrose, PG; Nicolau, DP; Nightingale, CH; Owens, RC; Quintiliani, R; Tessier, P, 2001) |
| "This study compared the efficacy and tolerability of once-daily dosing with either roxithromycin or cefixime in previously healthy adult patients aged between 18 and 60 with markers of uncomplicated community-acquired pneumonia (CAP) in three outpatient clinics in an open, randomized study." | 2.69 | Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. ( Fachinelli, H; Kijanczuk, S; Mingrone, H; Salvarezza, CR, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gökçe, İ | 1 |
| Çiçek, N | 1 |
| Güven, S | 1 |
| Altuntaş, Ü | 1 |
| Bıyıklı, N | 1 |
| Yıldız, N | 1 |
| Alpay, H | 1 |
| Demir, T | 1 |
| Dadali, M | 1 |
| Rawat, D | 1 |
| Hasan, AS | 1 |
| Capoor, MR | 1 |
| Sarma, S | 1 |
| Nair, D | 1 |
| Deb, M | 1 |
| Pillai, P | 1 |
| Aggarwal, P | 1 |
| Dreshaj, Sh | 1 |
| Doda-Ejupi, T | 1 |
| Tolaj, IQ | 1 |
| Mustafa, A | 1 |
| Kabashi, S | 1 |
| Shala, N | 1 |
| Geca, Nj | 1 |
| Aliu, A | 1 |
| Daka, A | 1 |
| Basha, N | 1 |
| Verhoef, J | 1 |
| Gillissen, A | 1 |
| Neu, HC | 1 |
| Chick, TW | 1 |
| Nathwani, D | 1 |
| Boyter, A | 1 |
| Fegan, PG | 1 |
| Davey, P | 1 |
| Salvarezza, CR | 1 |
| Mingrone, H | 1 |
| Fachinelli, H | 1 |
| Kijanczuk, S | 1 |
| Owens, RC | 1 |
| Tessier, P | 1 |
| Nightingale, CH | 1 |
| Ambrose, PG | 1 |
| Quintiliani, R | 1 |
| Nicolau, DP | 1 |
| Hamilton-Miller, JM | 1 |
| Calvo, A | 1 |
| Amores, R | 1 |
| Valero, E | 1 |
| Sevillano, D | 1 |
| Prieto, J | 1 |
2 reviews available for cefixime and Community Acquired Infection
| Article | Year |
|---|---|
Resistant Haemophilus influenzae in community-acquired respiratory tract infections: a role for cefixime.
Topics: Anti-Bacterial Agents; Cefixime; Community-Acquired Infections; Haemophilus Infections; Haemophilus | 2003 |
Overview of cefixime use in community-acquired infections.
Topics: Cefixime; Cephalosporins; Community-Acquired Infections; Escherichia coli Infections; Female; Haemop | 2000 |
4 trials available for cefixime and Community Acquired Infection
| Article | Year |
|---|---|
Clinical role of Cefixime in community-acquired infections.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Child; Child, Preschool; Community-Acquired Infe | 2011 |
Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections.
Topics: Adult; Aged; Ambulatory Care; Analysis of Variance; Anti-Bacterial Agents; Bacteria; Cefixime; Cefot | 1993 |
Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefixime; Cefotaxime; Cephalosporins; Community-Acquired I | 1998 |
Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.
Topics: Administration, Oral; Adult; Blood Bactericidal Activity; Cefixime; Ceftriaxone; Cephalosporins; Com | 2001 |
5 other studies available for cefixime and Community Acquired Infection
| Article | Year |
|---|---|
Changes in Bacterial Resistance Patterns of Pediatric Urinary Tract Infections and Rationale for Empirical Antibiotic Therapy.
Topics: Adolescent; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Cefazo | 2017 |
Recurrent complicated urinary tract infection due to rare pathogen Sphingomonas paucimobilis: contamination or real deal?
Topics: Anti-Bacterial Agents; Cefixime; Community-Acquired Infections; Diabetes Mellitus, Type 1; Diabetic | 2016 |
In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefixime; Clavulanic Acid; Community-Acquired Infections; Cr | 2009 |
Switch therapy in community-acquired pneumonia.
Topics: Administration, Oral; Anti-Infective Agents; Cefixime; Cefotaxime; Cephalosporins; Community-Acquire | 1996 |
[Activity of different antimicrobial agents against penicillin-resistant Streptococcus pneumoniae].
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Cefaclor; Cefixime; Cefpodoxime; Ceftibuten; Cefti | 2001 |